Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Other Non-Current Liabilities (2023 - 2026)

MBX Biosciences has reported Other Non-Current Liabilities over the past 4 years, most recently at $1000.0 for Q1 2026.

  • Quarterly results put Other Non-Current Liabilities at $1000.0 for Q1 2026, down 95.65% from a year ago — trailing twelve months through Mar 2026 was $1000.0 (down 95.65% YoY), and the annual figure for FY2025 was $2000.0, down 95.24%.
  • Other Non-Current Liabilities reached $1000.0 in Q1 2026 per MBX's latest filing, down from $2000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $194000.0 in Q4 2023 and bottomed at $1000.0 in Q1 2026.
  • Median Other Non-Current Liabilities over the past 4 years was $19000.0 (2025), compared with a mean of $44000.0.
  • The largest annual shift saw Other Non-Current Liabilities plummeted 78.35% in 2024 before it tumbled 95.65% in 2026.
  • Over 4 years, Other Non-Current Liabilities stood at $194000.0 in 2023, then tumbled by 78.35% to $42000.0 in 2024, then tumbled by 95.24% to $2000.0 in 2025, then tumbled by 50.0% to $1000.0 in 2026.
  • Business Quant data shows Other Non-Current Liabilities for MBX at $1000.0 in Q1 2026, $2000.0 in Q4 2025, and $7000.0 in Q3 2025.